NEW YORK, Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a long-term SNDX stockholder please contact Justin Kuehn, Esq. here, by email at [email protected], or call (833) 672-0814. The consu ...

NEW YORK, Dec. 19, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX).If you are a shareholder of Syndax Pharmaceuticals, Inc. and are interested in obtaining additional information regarding this investigation, free of charge, please visit us at: https://pjlfirm.com/syndax-pharmaceuticals-inc/You may ...

–      Primary endpoint met with CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R mNPM1 AML patients (p-value = 0.0014) ––      47% (30/64) ORR in a heavily pre-treated population, including 75% with prior venetoclax exposure in the efficacy population ––      Favorable safety and tolerability profile; only 5% of patients discontinued due to treatment-related adverse events ––      Results highlight consistency of revumenib's compelling clinical profile ––      sNDA filing in R/R mNPM1 AML expected in 1H25, ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Neil Gallagher - President & Head, R&D Steve Closter - Chief Commercial Officer Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Strategy Officer Conference Call Participants Priyanka Grover - JPMorgan Brad Canino - Stifel Peter Lawson - Barclays Chris Shibutani - Goldman Sachs Kelly Shi - ...

| --- | --- | --- | --- | |-------------------------------------|-------|-------|-----------------------------------------------------------------| | | | | | | | | | | | Syndax Reimagining Cancer Treatment | | | | | | | | Third Quarter Financial Results Presentation / November 5, 2024 | Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipa ...

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.98 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.27%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.91 per share when it actually produced a loss of $0.80, delivering a surprise of 12.09%.Over the last four quarters, ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Oth ...

Exhibit 99.1 Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update – New revumenib and Niktimvo™clinical data will be highlighted at 66 th ASH Annual Meeting – – mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 – – Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 – – Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic t ...

–  New revumenib and Niktimvo™ clinical data will be highlighted at 66th ASH Annual Meeting –– mNPM1 AML topline data from AUGMENT-101 expected in 4Q24; potential sNDA filing in 1H25 –– Revumenib NDA in R/R KMT2Ar acute leukemia is being reviewed under RTOR; PDUFA action date of December 26, 2024 –– Niktimvo approved by U.S. FDA for treatment of chronic GVHD after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg ––  $350 million royalty funding ...

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Company through profitability; proforma cash approaching $800 million as of June 30WALTHAM, Mass. and NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (axati ...